ArticlePloS one2024
Increasing prevalence of cirrhosis among insured adults in the United States, 2012-2018.
Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- Social Disadvantage and Disparities in Chronic Liver Disease: A Systematic Review.The American journal of gastroenterology · 2024Pooled it
- Clinical Outcomes After Percutaneous Coronary Intervention in Patients With Cirrhosis: A Multicentre National Study.Alimentary pharmacology & therapeutics · 2026Article
- The rate of and risk factors for falls among patients with cirrhosis: A multicenter study.Hepatology communications · 2026Article
- [Burden and epidemiological trends of alcohol use disorder and alcoholic liver disease in the Asia-Pacific region].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Review
- A Growing Mortality Divide: Demographic and Regional Disparities in Cirrhosis With Renal Failure, U.S. 1999-2023.Journal of immigrant and minority health · 2026Article
- Standardization of the Cirrhosis Admission Process and Its Impact on Inpatient Management and Patient Outcomes.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
- Role of social determinants and outcomes of patients with alcohol-associated liver disease referred for early liver transplantation: A multicenter analysis.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2026Article
- Spontaneous Recovery and Mortality in Patients With ALD Referred for Early Liver Transplantation.The American journal of gastroenterology · 2026Article
- Article
- Pregnancy outcomes among medically complex populations with high risk of pregnancy mortality in Virginia: a retrospective observational study.BMC medicine · 2026Observational
- Emerging Trends in Patients Hospitalised With Cirrhosis-Aetiologies, Complications and Outcomes Compared to Other Chronic Health Conditions.Alimentary pharmacology & therapeutics · 2025Article
- Comparing the cost of cirrhosis to other common chronic diseases: A longitudinal study in a large national insurance database.Hepatology (Baltimore, Md.) · 2025Article
- Where Do Patients With Cirrhosis Die? A CDC WONDER Analysis From 1999 to 2020.JGH open : an open access journal of gastroenterology and hepatology · 2025Article
- Hepatocellular Carcinoma Among Patients With Metabolic Dysfunction Associated Steatotic Liver Disease.Gastro hep advances · 2025Article
- Disparities in hepatitis C among people aged 12-59 with no history of injection drug use, United States, January 2013-March 2020.Liver international : official journal of the International Association for the Study of the Liver · 2024Article
- Top-Down Proteomics Identifies Plasma Proteoform Signatures of Liver Cirrhosis Progression.Molecular & cellular proteomics : MCP · 2024Article
- Nonalcoholic steatohepatitis/metabolic dysfunction-associated steatohepatitis emerging market: Preparing managed care for early intervention, equitable access, and integrating the patient perspective.Journal of managed care & specialty pharmacy · 2024Review
- Top-Down Proteomics Identifies Plasma Proteoform Signatures of Liver Cirrhosis Progression.bioRxiv : the preprint server for biology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundLiver cirrhosis is a chronic disease that is known as a "silent killer" and its true prevalence is difficult to describe. It is imperative to accurately characterize the prevalence of cirrhosis because of its increasing healthcare burden.
methodsIn this retrospective cohort study, trends in cirrhosis prevalence were evaluated using administrative data from one of the largest national health insurance providers in the US. (2011-2018). Enrolled adult (≥18-years-old) patients with cirrhosis defined by ICD-9 and ICD-10 were included in the study. The primary outcome measured in the study was the prevalence of cirrhosis 2011-2018.
resultsAmong the 371,482 patients with cirrhosis, the mean age was 62.2 (±13.7) years; 53.3% had commercial insurance and 46.4% had Medicare Advantage. The most frequent cirrhosis etiologies were alcohol-related (26.0%), NASH (20.9%) and HCV (20.0%). Mean time of follow-up was 725 (±732.3) days. The observed cirrhosis prevalence was 0.71% in 2018, a 2-fold increase from 2012 (0.34%). The highest prevalence observed was among patients with Medicare Advantage insurance (1.67%) in 2018. Prevalence increased in each US. state, with Southern states having the most rapid rise (2.3-fold). The most significant increases were observed in patients with NASH (3.9-fold) and alcohol-related (2-fold) cirrhosis.
conclusionBetween 2012-2018, the prevalence of liver cirrhosis doubled among insured patients. Alcohol-related and NASH cirrhosis were the most significant contributors to this increase. Patients living in the South, and those insured by Medicare Advantage also have disproportionately higher prevalence of cirrhosis. Public health interventions are important to mitigate this concerning trajectory of strain to the health system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.